Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06030362
Other study ID # IRB 22-000796
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 18, 2023
Est. completion date July 31, 2026

Study information

Verified date September 2023
Source University of California, Los Angeles
Contact Allison Vaughan, MPH
Phone 3108257206
Email GuptaLab@mednet.ucla.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current standard of care for obesity is the optimal management of comorbid conditions such as diabetes and hyperlipidemia, and counseling on diet, weight loss, or increased physical activity programs. However, lifestyle, diet, and behavioral interventions may provide between 7-10% reduction in initial weight and even fewer with long-term weight loss. In severely obese patients (BMI>40 or BMI>35 with comorbidities), bariatric surgery is also a potential treatment, but there is a high barrier for patients to undergo surgery for weight loss. These barriers include an aversion to major abdominal surgery, long recovery time, potential risk of vitamin deficiency, and risk for abdominal pain. For these reasons, there is a paramount need for other treatments for obesity and for food addiction. The current standard of care for obesity and food addiction is difficult to implement and lacks sustained efficacy. Most struggle to complete treatment, lose minimal weight, lack sustained weight loss, and engage in the well-known "YoYo" diet phenomenon. While bariatric surgery is currently the only effective treatment for obesity, there are several barriers associated with it such as eligibility requirements, invasiveness, difficult recovery, and cost making it not readily available for everyone. Some approved medications that help with obesity, such as orlistat, lorcaserin, or naltrexone-bupropion, have not been widely adopted by providers or patients due to their limited responses and adverse side effects. Probiotic cocktails have shown to be safe with little to no side effects. Preclinical models of probiotics demonstrate the ability to curb obesity in animal models. Therefore, a probiotic that is able to show significant weight loss along with lifestyle modifications would be highly adopted and desirable.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date July 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Ages 18-50 - BMI 25-40 - Male and Female - Not Pregnant or Nursing Exclusion Criteria: - Co-morbidities including but not limited to: - Type 1 (insulin dependent) diabetes - vascular disease - drastic weight loss (more than 10lbs over the preceding 2months) - frequent strenuous exercise (i.e. marathon runners/heavy weight lifting) - abdominal surgeries including weight loss surgery or partial/complete resection of stomach or bowel - untreated thyroid disease - neurological disease - Major medical condition the PI/MD feels would put the subject at risk or interfere with data collection. - Chronic pain - Diagnosed DSM IV active psychiatric illness including eating disorders. Must not be active or present for at least 2 years. Participants with a positive endorsement on the MINI+ will be excluded. - Using medications known to affect hunger/satiety/appetite - Pregnant, lactating, postpartum less than 6months. - Women of childbearing potential who are not practicing birth control or are planning to get pregnant during the study. - Use of oral/IV antibiotics within the last 3 months - Use of probiotics in the last 3 months. - Heavy use of alcohol and drugs will be determined by a positive endorsement on the MINI+. If the MINI+ is positive for alcohol or drug dependence or abuse, the participant will be excluded. In regards to tobacco use, participants will be excluded if they smoke more than 1/2 pack per day. - Cannabis use will not be exclusionary. If the MINI+ is positive for drug dependence or abuse, the participant will be excluded. - Significant change in usual diet and/or weight loss of more than 10lbs in the last 2 months. - Anyone taking medicines on the medication exclusion list. - Non-English Speakers (due to the use of validated questionnaires and limited availability of translated copies, participants must be fluent in English so that they will be able to read and follow directions easily. - Maintenance pharmacotherapies will not be exclusionary so long as they have been on a stable dose for 6months. - Body weight at enrollment greater than 400lbs. - Exclude from Optional MRI if: participant is unable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign bodies, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic
Dietary Supplement taken once daily for 3 months (90 days).
Placebo
Dietary Supplement taken once daily for 3 months (90days).

Locations

Country Name City State
United States University of California Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Differences in Multimodal Brain Signatures Neuroimaging of a subset of participants brain via magnetic resonance imaging (MRI) procedure. Optional - Measured twice, once at baseline (week 0) and once at end of study (week 12) visit. Lasting approximately 1.5hours.
Primary Differences in metabolite concentrations pre & post intervention - Stool Measurement of metabolomics via stool specimen. Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).
Primary Differences in metabolite concentrations pre & post intervention - Blood Measurement of metabolomics via blood specimen. Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).
Primary Differences in microbiome levels pre & post intervention - Stool 16S RNA sequencing to measure microbiome levels via stool specimen. Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).
Primary Differences in microbiome levels pre & post intervention - Blood 16S RNA sequencing to measure microbiome levels via blood specimen. Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).
Primary Differences in microbiome levels pre & post intervention - Stool Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen. Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).
Primary Differences in microbiome levels pre & post intervention - Blood Shotgun metagenomics, sequencing to measure microbiome levels via blood specimen. Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).
Secondary Differences in Subjective Stress Response - PANAS Between and within group differences on the negative affect subscale from the Brief Positive Affect and Negative Affect Scale (PANAS) before and after the laboratory stress tasks. PANAS scores can range from 10-50 for both the positive and negative affect, with the lower scores representing lower levels of positive/negative affect, and higher scores representing higher levels of positive/negative affect. Lasting approximately 10 minutes, measured pre & post the laboratory stress tasks, at baseline (week 0) and end of study (week 12).
Secondary Changes in Autonomic Measures - Heart Rate Variability Between and within group differences in overall average change in heart rate variability pre and post each laboratory stress task. Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visits, lasting approximately 1 hour.
Secondary Changes in Autonomic Measures - Skin Conductance Between and within group differences in overall average change in skin conductance response (SCR) pre and post each laboratory stress task measured using BIOPAC GSR (galvanized skin response) 100C system. Measured in Hz. Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visit. Lasting approximately 1 hour.
Secondary Changes in Autonomic Measures - Diastolic & Systolic blood pressure Between and within group differences in overall average change in both diastolic and systolic blood pressure pre and post each laboratory stress task. Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visit. Lasting approximately 1 hour.
Secondary Differences in Attention/Executive Function - Color Stroop Between and within group differences on the time it takes to complete the Color Stroop attention/executive function lab stress task. Lasting approximately 10minutes, measured at baseline (week 0) and end of study (week 12).
Secondary Differences in Attention/Executive Function - Trails A & B Between and within group differences on the time it takes to complete the Trails A & B attention/executive function lab stress task. Lasting approximately 10minutes, measured at baseline (week 0) and end of study (week 12).
Secondary Differences in Emotional Arousal System - IAPS task Between and within group differences in valence and emotional arousal ratings during the International Affective Picture System (IAPS) task. Lasting approximately 15minutes, measured at baseline (week 0) and end of study (week 12).
Secondary Systolic and Diastolic Blood Pressure Measurement of the pressure of circulating blood at rest Measured three times, once at each in-clinic appointment (week 0, week 6, week 12).
Secondary Anthropometrics - BMI Measurement of height(in) & weight(lbs), used to calculate body mass index (BMI). Measured three times, once at each in-clinic appointment (week 0, week 6, & week 12)
Secondary Questionnaire Data - Diet Use of validated surveys including the Food Frequency questionnaire, Food Choice Questionnaire. Self-Reported by the participant at home, collected 3 times (1) before beginning the dietary supplement, (2) at least 1 week before the mid-study appointment, and (3) within 1 week of finishing the 90-day dietary supplement.
Secondary Questionnaire Data Use of validated surveys to assess ingestive behaviors, stress, health, physical activity, etc. Self-Reported by the participant at home, collected 3 times (1) before beginning the dietary supplement, (2) at least 1 week before the mid-study appointment, and (3) within 1 week of finishing the 90-day dietary supplement.
Secondary Anthropometrics - waist and hip circumference Measurement of waist and hip circumference (cm). Measured three times, once at each in-clinic appointment (week 0, week 6, & week 12)
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2